Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 19/20 | 0.70 |
| ▸ | BCL2 | P10415 | 13/20 | 0.54 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.49 |
| ▸ | ALB | P02768 | 1/20 | 0.49 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2027016 | 1.00 | BCL2L1 (0.70) | BCL2L1BCL2BCL2L2ALBDOT1L | |
| SCHEMBL1541685 | 0.87 | BCL2L1 (0.88) | BCL2L1BCL2BCL2L2ALBDOT1L | |
| SCHEMBL1542046 | 0.85 | BCL2L1 (0.89) | BCL2L1BCL2BCL2L2ALBDOT1L | |
| SCHEMBL27671268 | 0.85 | BCL2L1 (0.89) | BCL2L1BCL2BCL2L2ALBDOT1L | |
| SCHEMBL2674775 | 0.83 | BCL2L1 (0.69) | BCL2L1BCL2BCL2L2ALBDOT1L | |
| SCHEMBL2674778 | 0.83 | BCL2L1 (0.69) | BCL2L1BCL2BCL2L2ALBDOT1L | |
| SCHEMBL29686481 | 0.83 | BCL2L1 (1.00) | BCL2L1BCL2BCL2L2ALB | |
| SCHEMBL554723 | 0.83 | BCL2L1 (1.00) | BCL2L1BCL2BCL2L2ALB | |
| SCHEMBL376632 | 0.83 | BCL2L1 (1.00) | BCL2L1BCL2BCL2L2ALB | |
| SCHEMBL2950088 | 0.83 | BCL2L1 (0.63) | BCL2L1BCL2BCL2L2ALBDOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173811-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110256129-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2011-10-20 | — | — | US | disclosed |
| US-7973161-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110144112-A9 | APOPTOSIS PROMOTERS | ABBVIE INC. | 2011-06-16 | — | — | US | disclosed |
| EP-2308812-A2 | N-acylsulfonamide apoptosis promoters | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100240715-A1 | Apoptosis promoters | ABBOTT LABORATORIES | 2010-09-23 | — | — | US | disclosed |
| US-7642260-B2 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144112-A9 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885BCL2L2 16/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 4/4885BCL2 3/4885BCL2L2 18/4885 |
| US-20060258657-A1 | Apoptosis promoters | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885BCL2L2 16/4885 |
| US-20100240715-A1 | Apoptosis promoters | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885BCL2L2 16/4885 |
| US-20110256129-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885BCL2L2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.